Business
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software SOLANA BEACH, Calif., March 11, 2024 (GLOBE NEWSWIRE) --
About this update from Clearpoint Neuro Inc.
[{"type":"text","content":"ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software\nSOLANA BEACH, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that preclinical results of an in vivo validation study have been published in the Journal of Neurosurgery.1 These data demonstrate that the ClearPoint Prism Neuro Laser Therapy System provides accurate, near real-time temperature of the brain tissue with a mean absolute error of","length":1186,"tagName":"div"}]